Agilent Technologies, Inc.A
NYSE • Healthcare
$114.70
P/E
25.32
PEG
0.06
FCF Yield
—
Rev Growth YoY
+814.0% YoY
Gross Margin
5260.0%
Health Score
5/10
D/E Ratio
0.50
Confidence
LOW
Business Snapshot
Agilent Technologies is a life sciences, diagnostics, and applied chemical analysis company serving pharmaceutical, clinical, environmental, and research markets worldwide. Its products include laboratory instruments, consumables, and software used in diagnostics and research workflows. Based on available valuation ratios and price data, Agilent sits in the large-cap tier, though an exact market capitalisation figure is not available for this analysis.
Financial Health
Score: 5/10
The reported gross margin of 5,260% and net margin of 1,826% are arithmetically implausible figures that almost certainly reflect a data normalisation or base-period distortion rather than genuine operating reality — they must be treated with extreme caution. On the positive side, the debt/equity ratio of 0.5x is manageable and well within a zone of financial stability, and the current ratio of 1.96x suggests adequate short-term liquidity (assets nearly doubling liabilities)...
Risk Assessment
- DATA INTEGRITY: Gross margin of 5,260% and net margin of 1,826% are statistically impossible for an operating business, indicating a serious data anomaly that undermines financial analysis.
- TECHNICALS: A confirmed death cross pattern (50-day MA crossing below 200-day MA) signals medium-term bearish momentum, with the price sitting below both moving averages.
- EARNINGS QUALITY: Only 1 of the last 4 quarters beat analyst estimates, a 25% beat rate that suggests consistent downside surprises relative to expectations.
- VALUATION OPACITY: No DCF fair value, no TTM revenue, and no TTM net income are available, making it impossible to anchor a fundamental valuation with confidence.
- PRICE WEAKNESS: At $114.70, the stock is trading 28.4% below its 52-week high of $160.27, reflecting sustained selling pressure over the past year.
---...
**Score: 5/10** The reported gross margin of 5,260% and net margin of 1,826% are arithmetically implausible figures that almost certainly reflect a data normalisation or base-period distortion rather than genuine operating reality — they must be treated with extreme caution. On the positive side, the debt/equity ratio of 0.5x is manageable and well within a zone of financial stability, and the current ratio of 1.96x suggests adequate short-term liquidity (assets nearly doubling liabilities). However, free cash flow is unavailable, making it impossible to assess the quality of earnings or the company's ability to self-fund growth and return capital to shareholders — a significant analytical gap. ---
- **DATA INTEGRITY: Gross margin of 5,260% and net margin of 1,826% are statistically impossible for an operating business, indicating a serious data anomaly that undermines financial analysis.** - **TECHNICALS: A confirmed death cross pattern (50-day MA crossing below 200-day MA) signals medium-term bearish momentum, with the price sitting below both moving averages.** - **EARNINGS QUALITY: Only 1 of the last 4 quarters beat analyst estimates, a 25% beat rate that suggests consistent downside surprises relative to expectations.** - **VALUATION OPACITY: No DCF fair value, no TTM revenue, and no TTM net income are available, making it impossible to anchor a fundamental valuation with confidence.** - **PRICE WEAKNESS: At $114.70, the stock is trading 28.4% below its 52-week high of $160.27, reflecting sustained selling pressure over the past year.** ---
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives